Monograph Details
|
|
Musculoskeletal Disorders
> Bone disorders
|
|
MIACALCIN |
| Manufacturer |
|
Novartis Pharmaceuticals Corp |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Hormone. |
| Generic Name |
|
Calcitonin-salmon 200Units/spray; nasal spray. |
| Also |
|
• MIACALCIN INJECTION
|
| Indications |
|
Postmenopausal osteoporosis. |
| Children |
|
Not applicable. |
| Adults |
|
1 spray (200Units) in alternating nostrils daily. |
| Precautions |
|
For nasal spray: do periodic nasal exams; discontinue if severe ulceration occurs. For inj: monitor for hypocalcemic tetany initially and urine sediments in chronic use; serum alkaline phosphatase and hydroxyproline in Paget's. Postmenopausal osteoporosis: supplement diet with calcium (1g/day) and Vit.D; reevaluate periodically. Pregnancy (Cat.C), nursing mothers: not recommended. |
| Adverse Reactions |
|
Nasal spray: rhinitis and other nasal/respiratory symptoms, back pain, GI upset. Inj: GI upset, local inflammation, flushing, rash, antibody formation. |
| How Supplied |
Nasal spray (3.7mL)—1 (30 doses)
Inj (2mL) vial—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
